- Email: [email protected]
Risperidone treatment of patients with chronic schizophrenia in a primary care setting
S328
P2. Psychotic disorders and antipqxhotics
References [l] Barnes, T.R.E., Braude, W.M., 1985. Akathisia variants and tardive dyskinesia. Arch. Gen. Psychiatry 42, 874-878. Sachdev, F!, 1994. Research diarmostic criteria for drue-induced akathisia: conceotualization. rationale aid proposal. Psychopharmacology 114, 181-18;. [2] Miller, C.H., Fleischhacker, W.W., 2000. Managing antipsychoticinduced acute and chronic akathisia. Drug Saf. 22, 73-81.
lP.2.175/ Olanzapine vs risperidone: Impact on weight gain and blood lipids. Is there any relationship with antipsychotic efficacy? D. Dimelis, G. Garyfallos, F. Kiouniakis, N. Sidiropoulos, G. Lavrendiadis, I. Giouzepas, K. Fokas. Aristotle Unioersi@ of Thessalonika, 2nd Unioersity Psychiatric Clinic, Thessalonika, Greece Objective: To determine weight gain and serum triglyceride elevation in patients treated with olanzapine or risperidone and their relationship to clinical improvement. Method: Fifty inpatients with schizophrenia, schizophreniform or schizoaffective disorder (DSM IV criteria) were assigned to monotherapy with olanzapine (N=25) or risperidone (N=25) for 8 weeks. At baseline and at week 8 the following were measured: weight, Body Mass Index (BMI), triglycerides, cholesterol and severity of psychopathology evaluated with the Positive and Negative Syndrome Scale (PANSS). Results: After 8 weeks, an increase of body weight of >I% was seen in 44 % of the olanzapine treated patients and only 4 % of the risperidone treated patients, p
IP2 176
Risperidone treatment of patients with chronic schizophrenia in a primary care setting
I. Nimatoudis. Aristotle University of Thessalonika, Thessaloniki, Greece The purpose of the open-label study was the investigation of the efficacy and safety profile of risperidone in the treatment of chronic schizophrenics in primary care setting. Risperidone monotherapy in doses 2-16 mgidaily was administered during a seven month period. All patients suffered from schizophrenia or schizoaffective disorder and were receiving antipsychotic medication. In total, 794 patients from 75 centers were analyzed at the end of the study.
The mean dose of risperidone at the study endpoint (7.3412.98 mgid) were higher than currently recommended doses (2-6 mg/d). The Positive and Negative Symptom Rating Scale (PANSS) was used to measure treatment efficacy. A statistical significant clinical improvement versus baseline was observed on total PANS& and all PANSS subscales. Extrapyramidal symptoms were evaluated by means of the Extrapyramidal Symptom Rating Scale (ESRS). A statistical significant decrease on ESRS score was found at study endpoint (baseline score: 18.7 (f6.4); endpoint: 13.3 (12.1), mean difference: 5.38, t=22.75 P
IP2 177 Atypical antipsychotics and cognitive brain activation in schizophrenia J. Quintana’, T. Wong’, E. Ortiz-Portillo’ , S. Marder’ , J.C. Mazziotta’. ‘UCLA Neuropsychiatric Institute and Hospital, Los Angeles, USA.; ‘UCLA School of Medicine, Los Angeles, U.S.A. Objective: To compare the effects of risperidone and olanzapine on brain activity during cognitive performance in patients with schizophrenia. Methods: We used functional magnetic resonance imaging to study brain activity in patients performing various working memory and facial affect discrimination (cognitive) tasks. Results: We analyzed data from 13 patients with chronic schizophrenia who had not been hospitalized or had a change in treatment for 1 year before study enrollment. Five patients were being treated with risperidone (3 to 6 mg/day) and 8 were receiving olanzapine (10 to 20 mgiday). We found treatmentgroup differences in brain activity during cognitive tasks. Patients treated with risperidone activated more critical areas during facial affect processing and anticipatory working memory, both of which are important in social functioning and decision making. Patients treated with risperidone or olanzapine activated similarly a distributed network involved in mnemonic working memory, an important but more logical cognitive process less directly linked to social functioning. Conclusions: Risperidone and olanzapine have specific effects on brain function during cognitive performance in patients with schizophrenia. Differential drug treatment may be possible based on neuropsychologic, cognitive, and neuroftmctional patient profiles.
P2. Psychotic disorders and antipqxhotics
References [l] Barnes, T.R.E., Braude, W.M., 1985. Akathisia variants and tardive dyskinesia. Arch. Gen. Psychiatry 42, 874-878. Sachdev, F!, 1994. Research diarmostic criteria for drue-induced akathisia: conceotualization. rationale aid proposal. Psychopharmacology 114, 181-18;. [2] Miller, C.H., Fleischhacker, W.W., 2000. Managing antipsychoticinduced acute and chronic akathisia. Drug Saf. 22, 73-81.
lP.2.175/ Olanzapine vs risperidone: Impact on weight gain and blood lipids. Is there any relationship with antipsychotic efficacy? D. Dimelis, G. Garyfallos, F. Kiouniakis, N. Sidiropoulos, G. Lavrendiadis, I. Giouzepas, K. Fokas. Aristotle Unioersi@ of Thessalonika, 2nd Unioersity Psychiatric Clinic, Thessalonika, Greece Objective: To determine weight gain and serum triglyceride elevation in patients treated with olanzapine or risperidone and their relationship to clinical improvement. Method: Fifty inpatients with schizophrenia, schizophreniform or schizoaffective disorder (DSM IV criteria) were assigned to monotherapy with olanzapine (N=25) or risperidone (N=25) for 8 weeks. At baseline and at week 8 the following were measured: weight, Body Mass Index (BMI), triglycerides, cholesterol and severity of psychopathology evaluated with the Positive and Negative Syndrome Scale (PANSS). Results: After 8 weeks, an increase of body weight of >I% was seen in 44 % of the olanzapine treated patients and only 4 % of the risperidone treated patients, p
IP2 176
Risperidone treatment of patients with chronic schizophrenia in a primary care setting
I. Nimatoudis. Aristotle University of Thessalonika, Thessaloniki, Greece The purpose of the open-label study was the investigation of the efficacy and safety profile of risperidone in the treatment of chronic schizophrenics in primary care setting. Risperidone monotherapy in doses 2-16 mgidaily was administered during a seven month period. All patients suffered from schizophrenia or schizoaffective disorder and were receiving antipsychotic medication. In total, 794 patients from 75 centers were analyzed at the end of the study.
The mean dose of risperidone at the study endpoint (7.3412.98 mgid) were higher than currently recommended doses (2-6 mg/d). The Positive and Negative Symptom Rating Scale (PANSS) was used to measure treatment efficacy. A statistical significant clinical improvement versus baseline was observed on total PANS& and all PANSS subscales. Extrapyramidal symptoms were evaluated by means of the Extrapyramidal Symptom Rating Scale (ESRS). A statistical significant decrease on ESRS score was found at study endpoint (baseline score: 18.7 (f6.4); endpoint: 13.3 (12.1), mean difference: 5.38, t=22.75 P
IP2 177 Atypical antipsychotics and cognitive brain activation in schizophrenia J. Quintana’, T. Wong’, E. Ortiz-Portillo’ , S. Marder’ , J.C. Mazziotta’. ‘UCLA Neuropsychiatric Institute and Hospital, Los Angeles, USA.; ‘UCLA School of Medicine, Los Angeles, U.S.A. Objective: To compare the effects of risperidone and olanzapine on brain activity during cognitive performance in patients with schizophrenia. Methods: We used functional magnetic resonance imaging to study brain activity in patients performing various working memory and facial affect discrimination (cognitive) tasks. Results: We analyzed data from 13 patients with chronic schizophrenia who had not been hospitalized or had a change in treatment for 1 year before study enrollment. Five patients were being treated with risperidone (3 to 6 mg/day) and 8 were receiving olanzapine (10 to 20 mgiday). We found treatmentgroup differences in brain activity during cognitive tasks. Patients treated with risperidone activated more critical areas during facial affect processing and anticipatory working memory, both of which are important in social functioning and decision making. Patients treated with risperidone or olanzapine activated similarly a distributed network involved in mnemonic working memory, an important but more logical cognitive process less directly linked to social functioning. Conclusions: Risperidone and olanzapine have specific effects on brain function during cognitive performance in patients with schizophrenia. Differential drug treatment may be possible based on neuropsychologic, cognitive, and neuroftmctional patient profiles.